Complete Genomics Well Positioned To Move From Research To Clinical In Genome Sequencing

Rod Raynovich submits:The IPO market is setting up for continued investor interest in the biotech sector.

By Medhanie:We knew the likelihood of Complete Genomics (GNOM) remaining an independent company was low. Given its low trading price, difficulty in gaining access to capital and its pending lawsuit with Illumina (ILMN), a sale almost seems inevitable.

Scientists around the world are anticipating the results of a Chinese study that would mark the first time DNA in a human embryo has been modified in a way that would carry into future generations. Although the embryos would be for study only, and not intended for implantation, the research would mark a significant milestone: the first time human DNA had been altered so substantially that it would change the “germ line” — the eggs or sperm of any child produced from the embryo.

A growing number of parents are getting their children genetically tested to find out their kids' risk for developing potentially devastating diseases.

By OneMedPlace: By Herina Ayot Keating Capital’s President Timothy Keating was interviewed by OneMedRadio where he describes the liquidity premium that gives public companies 3x valuation over private company peers and the dramatic decline in IPOs and increase in size that is debilitating economic growth.Click to hear audio and see below for a full transcript.

The Burrill Report submits: By Marie DaghlianDNA sequencing firm Complete Genomics (GNOM) went public after scaling back its deal price more than 30 percent to get it done. Shares began trading on the Nasdaq Global Market on Thursday under the symbol GNOM. The stock closed at $8.03, down more than 10 percent on the first day of trading with volume of nearly 2.5 million shares.